Related by context. All words. (Click for frequent words.) 56 Syllego system 56 NABTT 55 Trofex 55 Phase #b/#a clinical 55 Tumor Microenvironment 55 risk stratification 54 IASLC 54 ABRF 54 Corgentin 54 Acute Decompensated Heart Failure 54 PRESEPT 53 Ovarian Cancer Screening 53 DF HCC 53 PD2i ® 53 ASGCT 53 eIF 4E 53 Affymetrix microarray technology 53 Phase 1a clinical 53 Squalamine 53 ACRIN 53 Exelixis XL# 53 genomic biomarker 52 Cardiotoxicity 52 CEQ# 52 STRIDE PD 52 Refractory Angina 52 haplotype map 52 fosbretabulin 52 ATVB 52 florbetaben 52 Ovarian PLCO Cancer 52 HDL Selective Delipidation 52 ASSERT 52 QOPI 52 CardioFit 52 OLYMPIA registry 52 AFFiRiS 52 Patient Registry 52 multicentric 52 RNAi therapeutic targeting 52 TRO# 52 p# biomarker 52 Bone Marrow Transplantation 51 BARI 2D 51 Randomized Evaluation 51 MADIT 51 chemoresistant 51 Factor VIIa 51 PD2i R 51 SYN# 51 Risk Stratification 51 kidney urologic 51 DEcIDE 51 Phase Ib Clinical Trial 51 observational cohort study 51 phase IIa clinical 51 CHAMPION PCI 51 AlloMap testing 51 PDE# inhibitors 51 prospective multicentre 51 CRLX# 51 prospective multicenter study 51 genomewide association study 51 Phase Ib clinical 51 chronic myocardial ischemia 51 Lp PLA 2 51 Gastric Cancer 51 CTAP# Capsules 51 Bucindolol 51 ISHLT 50 antiproliferative effects 50 atherothrombosis 50 phase IIa 50 etiologic 50 Trandolapril 50 HORIZONS AMI trial 50 AIM HIGH 50 Trophos 50 multicenter randomized clinical 50 ISTH 50 EORTC NCI 50 AA Amyloidosis 50 Systemic Sclerosis 50 ATTR CM 50 Biodesix 50 SNT MC# 50 recurrent glioblastoma multiforme 50 NCCTG 50 Erythropoietic 50 multicenter trials 50 StemEx R 50 Prostate Lung Colorectal 50 vidofludimus 50 ENMD # 50 CIBMTR 50 REACH Registry 50 genitourinary cancers 50 ALN TTR 50 Interagency Registry 50 Acute Heart Failure 50 Oncologic 50 BCIRG 50 Panzem ® 50 clinico pathological 50 EchoCRT 50 Ocrelizumab 50 Digital Mammographic Imaging 50 Phase Ib II 50 placebo controlled Phase III 50 Quinamed 49 Blinatumomab 49 Clinicaltrials.gov 49 clinical pharmacology studies 49 EORTC 49 Symadex 49 cardio renal 49 Circulatory Support 49 investigational therapies 49 RE LY ® 49 Ischemic 49 neuropathologic 49 Renal Cell Carcinoma RCC 49 XYOTAX TM 49 Daxor 49 Primary Immunodeficiency 49 MADIT II 49 pharmacodynamic PD 49 CARE HF 49 phase IIb clinical 49 Dr. Ruoslahti 49 pretransplant 49 LUMINATE 49 smoldering multiple myeloma 49 SinuNase ™ 49 Clinical Antipsychotic Trials 49 vivo validation 49 Renal Cancer 49 ICAEL 49 Polymorphism 49 relapsing multiple sclerosis 49 Source MDx 49 Aviptadil 49 ImmuKnow R 49 clevidipine 49 Anceta 49 Cloretazine 49 Phase III psoriasis 49 Ataluren 49 Heart Transplant Recipients 49 Malignant Mesothelioma 49 MEND CABG 49 ASNR 49 Allogeneic 49 transplantation HSCT 49 Cloretazine R 49 number NCT# ClinicalTrials.gov 49 TEMSO 49 Adult Stem Cell Therapy 49 lorcaserin Phase 49 ASCO GI 49 Phase Ib study 49 GAMMAGARD 49 thoracic aortic disease 49 longitudinal cohort study 49 Prostate Disease 49 biliary cancer 49 INSPIRE Trial Phase III 49 Phase 2a Clinical Trial 49 Progenika 49 haematological cancers 49 genetic polymorphisms 49 TG MV 48 MTWA testing 48 multicenter phase 48 PLCO 48 CLARITY TIMI 48 GHIS 48 riociguat 48 microplasmin Phase III 48 ASCO GU 48 ICAAC IDSA 48 YONDELIS 48 EndoTAG TM -1 48 AIR2 Trial 48 Estrogen Receptor 48 Akt inhibitor 48 prostate cancer CaP 48 Biological Therapy 48 Intervention Effectiveness 48 PITX2 48 Hepatocellular Carcinoma 48 multicenter randomized controlled 48 Natalizumab 48 Prospective Multicenter 48 CanAg 48 PANVAC VF 48 small molecule activators 48 biostatistical analysis 48 Dalbavancin 48 Vascular Disease Foundation 48 neratinib 48 neoplastic diseases 48 BioGeneriX 48 ABCB1 48 receptor tyrosine kinase inhibitor 48 thetreatment 48 vinca alkaloid 48 TQT 48 Patient Outcomes 48 ganaxolone 48 retrospectively analyzed 48 Novel Therapeutic 48 BioNumerik 48 neoadjuvant treatment 48 soluble receptor 48 Fc fusion protein 48 Daclizumab 48 AACR #st Annual Meeting 48 REVIVE Diabetes 48 rALLy clinical trial 48 Anticancer Drug 48 Androxal TM 48 Hsp# Inhibitor 48 SWOG 48 ChromoCure 48 Myocardial Infarction 48 Morquio 48 Temsirolimus 48 CaPSURE 48 Ischemia 48 SMT C# 48 atherosclerotic disease 48 Angiolix 48 susceptibility loci 47 IPAH 47 Paediatric Endocrinology 47 Phenotype 47 MindUp BioResearch 47 Cloretazine ® 47 IL#B 47 preclinically 47 postmenopausal osteoporotic women 47 clinicopathological 47 Acute Myocardial Infarction 47 Virulizin R 47 #p# [003] 47 ZACTIMA 47 ELCAP 47 NKI AVL 47 MEND CABG II 47 miRagen 47 YONDELIS R 47 ACCORD Lipid 47 CIRSE 47 ATIR 47 pancreatic islet cell 47 Endoscopic Ablation System 47 Acute Coronary Syndrome 47 ENDEAVOR IV 47 Cardiovascular Therapeutics 47 Inflammatory Bowel Diseases 47 longitudinal observational study 47 dbGaP 47 NSABP B 47 IL# PE#QQR 47 Neuroprotection 47 refractory angina 47 EFNS 47 essential thrombocythemia ET 47 Candesartan 47 laparoscopic radical nephrectomy 47 depsipeptide 47 CVBT #H 47 ISEL 47 Clinical Therapeutics 47 ONTARGET 47 stem cell transplantations 47 ELSO 47 FDG PET imaging 47 RE LY trial 47 Amarantus 47 R roscovitine 47 MyoCell TM 47 acadesine 47 undergoing coronary angiography 47 scientific journal PNAS 47 Myelodysplastic syndromes MDS 47 ImmuKnow assay 47 KIF6 carriers 47 allogeneic hematopoietic cell 47 Antitumor 47 HYVET 47 ACC NCDR 47 ICON7 47 thorough QTc 47 Gynecological Cancer 47 cytoreductive nephrectomy 47 PROactive study 47 Human Proteome Organization 47 HORIZONS AMI 47 Gynecologic Cancer Society 47 Critical Limb Ischemia CLI 47 PEGylated interferon beta 1a 47 Acute Renal Failure 47 Fabry Disease 47 JAK2 Inhibitor 47 USpella 47 Hematopoietic 47 abnormal cytology 47 Investigator Initiated 47 ASCO Breast Cancer 47 multicenter prospective 47 Urocortin 2 47 SNCA 47 myeloproliferative disorders 47 differential gene expression 47 REALITY Trial 47 radionuclide therapy 47 ARRY # 47 Clinical Proteomics 47 BrachySil ™ 47 metastatic neuroendocrine tumors 47 Talabostat 47 CIMZIA TM certolizumab pegol 47 Investigational Drug 47 prostate carcinogenesis 47 Adjuvant therapy 47 MYTHOS trial 47 hypereosinophilic syndrome 47 Human Genetics ASHG 47 Sidec 47 Fibrosis 47 retrospective cohort study 47 OvaRex MAb 47 pharmacokinetic PK 47 Xanafide 47 CSF Assurance 47 Systemic Lupus Erythematosus SLE 47 VerifyNow P#Y# 47 Chronic Heart Failure 47 Aplidin 47 recurrent glioma 47 Cellular Therapy 47 MYH9 gene 47 Cell Transplant 47 HFSA 47 extracranial 47 STRATEGY FOR AN OPEN 47 ToGA 47 Hepatocellular Carcinoma HCC 47 occlusive disease 47 haematologic malignancies 47 hepatitis C HCV 47 ASCB 47 pharmacogenetic testing 46 ARVO 46 Echocardiographic 46 retrospective cohort 46 AASLD 46 Renal Artery 46 Marrow Transplant Research 46 Liver transplantation 46 Digestive Diseases Week 46 gene polymorphisms 46 CALGB 46 Vascular Wrap TM 46 Occlusive Disease 46 Lung Injury 46 Allograft 46 HeFT 46 Investigative Pathology 46 pharmacodynamic endpoints 46 FRDA 46 RTOG 46 idiopathic myelofibrosis 46 metastatic pancreatic 46 Actimmune ® 46 pathophysiological mechanisms 46 SSc 46 Granulocyte Colony Stimulating Factor 46 ON #.Na 46 genetic loci 46 MAPT 46 CCX# B 46 Diabetes Complications 46 GW# [003] 46 Inhaled AAT 46 gastric carcinoma 46 ECTRIMS 46 castrate resistant prostate cancer 46 Antisoma AS# 46 KRAS variant 46 beta 1a 46 RhuDex R 46 HDAC Inhibitor 46 Bronchiectasis 46 Annamycin 46 rALLy trial 46 Thrombolysis 46 Phase 1b clinical trials 46 Lung Transplantation 46 VKORC1 46 Islet Transplantation 46 Computed Tomographic 46 OvaDx 46 WTCCC 46 GRNCM1 46 RhuDex ® 46 Clusterin 46 Phase III HEAT 46 NSABP 46 pharmacokinetic PK study 46 MIVI TRUST 46 Asthma Intervention 46 International HapMap Consortium 46 Onconase 46 Trial PCPT 46 Phase III Clinical Trial 46 carcinoid 46 prospective longitudinal 46 Keystone Symposia 46 Alzhemed TM 46 clinically localized prostate 46 Autoimmune Diseases 46 histone acetyltransferase 46 genotype phenotype 46 substudy 46 myogenic cell 46 ONTARGET R 46 NICE SUGAR 46 NCDB 46 cardiac computed tomography 46 National Oncologic PET 46 eprotirome 46 PhG alpha 1 46 clinicopathologic 46 A1PI 46 Therapeutics TCT 46 INTERCEPT platelets 46 acute humoral rejection 46 epoetin alpha 46 Acute Stroke 46 NEVO RES 46 AmpliMed 46 prospectively defined 46 APEX AMI trial 46 Triapine R 46 Cellular Immunotherapy 46 PROLARIS 46 CGEMS 46 Stereotactic Body Radiation Therapy 46 metastatic malignant 46 preclinical efficacy 46 Liprostin 46 Dilated Cardiomyopathy 46 Virium 46 dose escalation clinical 46 CDKN2A 46 iSBTc 46 Afib 46 Acute Ischemic Stroke 46 anti fibrotic 46 PAOD 46 Primary Care Providers 46 Fibromyalgia Syndrome 46 #st Annual Meeting 46 HNPCC 46 prognostic biomarker 46 Granted Orphan Drug 46 XIENCE V Stent System 46 ColonSentry test 46 Val HeFT 46 Raymedica 46 CareManager 46 allogeneic hematopoietic stem cell 46 journal Transfusion 46 Insulin Resistance 46 Degarelix 46 Dialysis Outcomes 46 AAGP 46 APDA 46 Molecular Pathology 46 KRAS mutation 46 PREVU x LT 46 Surgical resection 46 vascular disrupting agent 46 MELAS 46 papillary renal cell carcinoma 46 prospective observational cohort 46 Arteriosclerosis 46 PITX2 methylation 46 ST Segment Elevation 46 Novel Inhibitor 46 Lipid 46 BCR ABL inhibitor 46 Safinamide 46 malignant pleural mesothelioma 45 Intensive Care Medicine 45 AAPM 45 Cancer Genetic Markers 45 Carotid Revascularization Endarterectomy vs. 45 Endocrine Society #st 45 Edge STudy 45 liver transplant recipients 45 Multicenter Phase 45 Hedgehog antagonist 45 Hemodialysis Patients 45 RhuDex ™ 45 Aryplase 45 Ceflatonin R 45 malignant phenotype 45 placebo controlled clinical 45 Connective Tissue Oncology 45 GWTG CAD 45 Renal Physicians 45 Eluting Stent 45 solid organ transplantation 45 Generx ™ 45 UEGW 45 Iron Overload 45 CAMMS# 45 gefitinib Iressa 45 Phase Ib IIa clinical 45 ACUITY trial 45 IMiDs ® compound 45 TNM staging 45 Translational Oncology 45 SABCS 45 Cervical Cytology 45 serum GGT 45 Marrow Transplant 45 JenaValve 45 chimeric monoclonal antibody 45 Adult Cardiac Surgery 45 MacuSight 45 ADHERE 45 ADVEXIN therapy 45 Severe Sepsis 45 ACOMPLIA R 45 EUS FNA 45 Elvitegravir 45 Dr. McHutchison 45 Geriatric Oncology 45 colorectal carcinoma 45 Serono Symposia International 45 Advanced Renal Cell 45 Centro Monzino 45 pharmacologic intervention 45 Delcath Phase III 45 ASBMR 45 Vidaza azacitidine 45 Enzyme Replacement Therapy 45 Limb Salvage 45 Gynecologic Oncology Group 45 COU AA 45 genomewide 45 Immune Mediated 45 ASGT 45 rhMBL 45 MYDICAR ® 45 SUTENT ® 45 trabectedin 45 patientswith 45 Oncogenic 45 ADNI 45 International HapMap Project 45 HF ACTION 45 Advanced Heart Failure 45 Cohort Consortium 45 BCG refractory 45 AIUM 45 psoriatic arthritis PsA 45 cardiovascular calcification 45 ENDEAVOR clinical 45 Vascugel 45 Proc Am Soc 45 Agendia BV 45 unstable angina UA 45 LTBI 45 Multicenter Automatic Defibrillator Implantation 45 NP2 Enkephalin 45 secretory phospholipase A2 sPLA2 45 Parkinson Disease PD 45 Chronic Lymphocytic Leukemia 45 Pancreas Transplant 45 CATIE AD 45 Breast Surgeons 45 prospective observational studies 45 busulfan 45 Eculizumab 45 novel vascular disrupting 45 CG# [003] 45 CLARITY study 45 metastatic malignant melanoma 45 multicenter randomized Phase 45 pharmacokinetic pharmacodynamic 45 Registry NOPR 45 ANTEGREN 45 Immunologists 45 HuMax EGFr 45 chromosome #p# [002] 45 histone deacetylase HDAC inhibitor 45 PFO migraine 45 AACVPR 45 PARTNER Trial 45 thrombophilia 45 T2D 45 T1D 45 sJIA 45 PARP inhibitor 45 lymphoid malignancies 45 OBJECTIVES 45 ISPOR 45 Neurodegenerative Disorders 45 NMIBC 45 Clavis Pharma ASA 45 Demonstrates Sustained 45 Acute MI 45 TCF#L# 45 Noscira 45 histologically proven 45 lymphoproliferative disorders 45 sargramostim 45 sCD# 45 RhuDex TM 45 Radiation Therapy Oncology 45 Prospective Randomized 45 localized prostate 45 Multiethnic Study 45 autologous hematopoietic stem cell 45 Trial NLST 45 Targeted Anticancer Therapies 45 ACCF AHA 45 Kidney Disease Outcomes 45 Oncology ASTRO 45 FDG PET 45 Tissue Repair 45 endophenotypes 45 APEX AMI 45 Preclinical Study 44 ENGAGE AF TIMI 44 IV NSCLC 44 LUX Lung 44 multicentre prospective 44 Decompensated Heart Failure 44 KIF6 gene variant 44 ProLindac TM 44 J Immunol 44 TRILOGY ACS 44 essential thrombocythemia 44 tanespimycin 44 CRMD# 44 ACCLAIM II 44 efficacy evaluable 44 metastatic colorectal 44 varespladib 44 Phase III Psoriasis 44 By JENNIFER LEARN 44 End Results SEER 44 polycythemia vera essential thrombocythemia 44 Biomolecular Screening 44 EURIDIS 44 undergone radical prostatectomy 44 histone deacetylase inhibitor 44 pediatric acute lymphoblastic 44 ALS MND 44 Welichem 44 CAMPATH 44 LV dysfunction 44 familial hypercholesterolemia 44 Li Fraumeni Syndrome 44 AVOREN 44 antiangiogenic agent 44 Gastrointestinal Oncology 44 Hematologic 44 prospective randomized multicenter 44 Duchenne muscular dystrophy DMD 44 FDG PET scans 44 HBeAg negative 44 Diasome 44 pain palliation 44 echocardiographic 44 coinfected patients 44 NLX P# 44 Polymorphisms 44 Microalbuminuria 44 metastatic renal cell 44 interstitial cystitis IC 44 Aneurysm Repair 44 Clavis Pharma 44 microtubule associated 44 Manja Bouman CEO 44 Arno Therapeutics 44 systolic hypertension 44 R vitespen 44 Laryngeal Cancer 44 Late Breaker 44 prostate carcinoma 44 Chemophase 44 Screening Trial DMIST 44 ExCell study 44 antiretroviral naïve 44 ExTRACT TIMI 44 hypophosphatasia 44 ASNC 44 atherothrombotic disease 44 Pancreatic 44 Fx #A 44 IIa clinical 44 ischemic cardiomyopathy 44 Diamyd ® 44 tolerability pharmacokinetics 44 Fresenius Biotech 44 Alocrest 44 prognostic variables 44 Phase 2b kidney transplant 44 syngeneic 44 phase IIb study 44 Pulmonary arterial hypertension 44 Chemokine 44 SIR Spheres 44 Intervention Effectiveness CATIE 44 clinically evaluable 44 Orqis Medical 44 ViaCyte 44 Carfilzomib 44 CC genotype 44 Hepatic 44 Sjogren Syndrome 44 familial amyloidotic polyneuropathy FAP 44 electrocardiography ECG 44 Stent Thrombosis 44 pancreatic adenocarcinoma 44 immunomodulatory agents 44 Cytogenetic 44 fibrotic disorders 44 Yondelis ® 44 Molecular Biology Organization EMBO 44 NOD mouse 44 transthyretin amyloidosis 44 Group RTOG 44 myelofibrosis polycythemia vera 44 lorvotuzumab mertansine 44 advanced hepatocellular carcinoma 44 pT2 44 Elisabeth Lindner CEO 44 Tavocept 44 Simulect 44 Acute Coronary Syndromes 44 Oral Mucositis 44 Myelodysplasia 44 HLA DRB1 * 44 fibrotic disease 44 Functional Neurosurgery 44 cortical stimulation 44 leukemia lymphoma Hodgkin 44 prostate adenocarcinoma 44 Telatinib 44 Histopathological 44 renal tumors 44 T1DM 44 Gleevec resistant 44 DiscoveryBioMed 44 retrospective observational study 44 carotid artery stenting CAS 44 susceptibility locus 44 Podium Presentation 44 Chronic lymphocytic leukemia 44 interferon gamma 1b 44 Serious Adverse Events 44 Evoltra ® 44 metastatic bladder 44 Cancer Gene Therapy 44 myeloproliferative neoplasms 44 ADPKD 44 Phase 2b Trial 44 contrast echocardiography 44 Chronic Obstructive Lung 44 Canvaxin 44 Velcade bortezomib 44 tumor subtypes 44 Prolor 44 Multicenter 44 Spine Arthroplasty Society 44 abstracts summarizing 44 hematopoietic cell 44 acute myeloid 44 relapsed MM 44 OX1 44 evaluating tivozanib 44 Pivotal Trial 44 peptidome 44 PERSEUS 44 Female Urology 44 Elafin 44 Chronic Lymphocytic Leukemia CLL 44 Medmarc 44 MyoCath R 44 Diabetic Macular Edema 44 UPLYSO 44 coronary revascularization 44 Nonalcoholic fatty liver 44 Meta analyzes 44 PROPEL 44 Radiology Imaging Network ACRIN 44 Proxinium TM 44 BRCA testing 44 Phase 2b Clinical Trial 44 mRCC 44 Medidur ™ FA 44 CIMZIA ™ 44 HIV HCV coinfected 44 ADVEXIN clinical 44 Immunohistochemistry 44 ECCMID 44 Myelodysplastic Syndromes 44 Prostate Cancer Prevention 44 Tyrosine Kinase Inhibitors 44 HepaSphere 44 Myelodysplastic syndrome 44 atherothrombotic 43 ECASS 43 Heart Failure Trial 43 CEUS 43 Initiates Phase 2b 43 bardoxolone methyl 43 PON1 activity 43 acetonide FA 43 TMPRSS2 ERG fusion 43 relapsed leukemia 43 GRAVITAS trial 43 Panzem 43 DiaGenic 43 Coronary Tree 43 Angiox R 43 StemEx 43 ARC# [001] 43 randomizing patients 43 Diabetes ACCORD 43 metastatic hormone refractory 43 EAACI 43 TAXUS TM 43 Coronary artery bypass grafting 43 Apaziquone 43 darinaparsin ZIO 43 Intervention Trial GAIT 43 Clinical Oncology Annual Meeting 43 SNT-MC#/idebenone 43 DiaGenic ASA 43 ECCO ESMO 43 CYP#C# [001] 43 Hypertriglyceridemia 43 randomized blinded 43 Antihypertensive 43 chromosome #q#.# [002] 43 recurrent NSCLC 43 underwent resection 43 SPIVA methodology 43 Amorcyte 43 Malignant Melanoma 43 Pulmonary Hypertension 43 cancer mCRC 43 Atypical Hemolytic Uremic Syndrome 43 COPERNICUS 43 unresectable liver cancer 43 Therapeutic Radiation 43 invasive lobular carcinoma 43 Acute renal failure 43 Multiple Ascending Dose 43 atherosclerosis regression 43 epithelial tumors 43 HGPIN 43 Cognitive Aging 43 PreDx DRS 43 smoldering myeloma 43 unoprostone isopropyl 43 CONBRIZA 43 optica 43 vWD 43 HSCT 43 Pediatric Oncology Branch 43 ALN HTT 43 resected pancreatic cancer 43 histopathological 43 null responder 43 Pharmacodynamic 43 FDG PET CT 43 null responder HCV 43 histamine dihydrochloride 43 Pseudomonas aeruginosa infections 43 BRCA2 mutation carriers 43 #p# [001] 43 Catena ® 43 Chronic Kidney Disease 43 CSPG 43 CALGB # [002] 43 basal cell carcinoma BCC 43 invasive bladder 43 Cholangiocarcinoma 43 Leber Hereditary Optic Neuropathy 43 Arthroplasty 43 Bendavia 43 idiopathic pulmonary arterial hypertension 43 Leukemia Lymphoma 43 histopathologic diagnosis 43 Affimed Therapeutics AG 43 PIDD 43 Hematological 43 IFOS 43 Transthyretin 43 NOD SCID mice 43 myocardial viability 43 chronic granulomatous disease 43 Framingham Offspring Study 43 Triapine 43 Biomerk Tumorgrafts 43 FOCIS 43 histologically confirmed 43 carcinoid tumors 43 squamous cell lung cancer 43 Stop Hypertension DASH 43 Other OTC BVTI 43 Clinical Genetics 43 TAXUS VI 43 NMO 43 ARDIS 43 prospective observational 43 genetic variants associated 43 Alpha Tocopherol Beta Carotene 43 Raptiva R 43 ATACAND 43 PEG SN# 43 ESHRE 43 Certican 43 pan HDAC inhibitor 43 Zenvia Phase III 43 Omacetaxine 43 kidney allograft 43 Movement Disorder 43 Oxidized LDL 43 Interpersonal Psychotherapy 43 Multivariate logistic regression 43 Echocardiography 43 Bladder Cancer 43 Progressive Multifocal Leukoencephalopathy 43 cangrelor 43 BR.# 43 Epirubicin 43 Marrow Transplantation 43 phase IIIb 43 Endovascular Valve Edge 43 micrometastases 43 TRITON TIMI 43 prostate cancer CRPC 43 Solid Tumors 43 Inclinix 43 DBMD 43 Troxatyl 43 subclinical atherosclerosis 43 CP CPPS 43 EBMT 43 Idiopathic pulmonary fibrosis 43 acute coronary syndromes ACS 43 favorable pharmacokinetic profile 43 Hyperlipidemia 43 trodusquemine 43 CAPRIE 43 NABT 43 patients undergoing percutaneous 43 LDH lactate dehydrogenase 43 Nilotinib 43 TRA 2P 43 ug dose 43 bevacizumab Avastin ® 43 antithrombotic 43 Idiopathic Pulmonary Fibrosis 43 AtherOx 43 SHPT 43 ENTB 43 Bioanalysis 43 Zenvia ™ 43 PCI percutaneous coronary 43 benign prostatic hypertrophy BPH 43 biostatisticians 43 nonmetastatic 43 Curon Medical 43 perinatal morbidity 43 pharmacoeconomic analysis 43 Zevalin consolidation 43 Cornea Donor Study 43 ACCF 43 cyclophilin inhibitors 43 Urologic 43 membranous nephropathy 43 Dual Antiplatelet Therapy 43 liver metastases 43 Histocompatibility 43 Pulmonary Arterial Hypertension 43 myasthenia gravis MG